Review
Cell Biology
Anna Ianza, Marianna Sirico, Ottavia Bernocchi, Daniele Generali
Summary: Studies over the past two decades have shown the involvement of IGF-1 in various patho-physiological processes and tumor development, particularly in breast cancer where overexpression and hyperphosphorylation of IGF-1R are common. The IGF-1 axis is closely linked to estrogen regulation, potentially offering a solution to anti-estrogen resistance, and may also impact other therapeutic strategies for cancer treatment.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Oncology
Adam Hermawan, Herwandhani Putri, Naufa Hanif, Nurul Fatimah, Heri Himawan Prasetio
Summary: This study used a bioinformatics approach and in vitro experiments to assess the target genes of Honokiol (HON) against breast cancer resistance to tamoxifen (TAM). The results suggest that HON may overcome TAM resistance in breast cancer by targeting FGFR2, RET, ERBB4, MMP16, FN1, and SOX2. However, further studies are needed to validate these findings.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Ranim M. Kotb, Safinaz S. Ibrahim, Osama M. Mostafa, Nancy N. Shahin
Summary: This study investigates the role of CXCR4 in trastuzumab resistance in breast cancer patients and found that high CXCR4 expression is associated with recurrence and is an independent predictor of progression risk after therapy. HIF-1 alpha, HuR, and ITCH are significantly associated with clinical outcome. In chemotherapy-treated patients, neither CXCR4 nor any of its regulators are associated with recurrence or predicted disease progression risk.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
(2022)
Review
Medicine, Research & Experimental
Tianshu Zhang, Huimin Zhou, Kexin Wang, Xiaowei Wang, Mengyan Wang, Wenxia Zhao, Xiaoming Xi, Yang Li, Meilian Cai, Wuli Zhao, Yanni Xu, Rongguang Shao
Summary: Breast cancer is one of the most common malignant tumors in women and its occurrence has become the biggest threat. Understanding the characteristics and molecular mechanisms of breast cancer stem cells is crucial for developing targeted drugs.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Review
Oncology
Ilana Schlam, Paolo Tarantino, Sara M. Tolaney
Summary: This article summarizes the resistance mechanisms to HER2-targeted treatments and discusses the potential strategies to overcome them in order to improve outcomes for breast cancer patients.
Article
Biochemistry & Molecular Biology
Jayoung Song, Ahreum Kim, Intaek Hong, Sangji Kim, Woong Sub Byun, Hyun Soo Lee, Hyung Sik Kim, Sang Kook Lee, Yongseok Kwon
Summary: In this study, atropisomeric 8-aryltetrahydroisoquinolines were synthesized and evaluated for their biological activities. A highly bioactive racemic compound was produced, showing high antiproliferative activities against various cancer cell lines, including docetaxel-resistant breast cancer cell lines. Each enantiomer could be selectively synthesized using chiral phosphoric acid-catalyzed atroposelective Pictet-Spengler cyclization. The (R)-enantiomer exhibited higher biological activity compared to the (S)-enantiomer and overcame docetaxel resistance in triple-negative breast cancer cell lines via downregulation of STAT3 activation, inducing cellular apoptosis.
BIOORGANIC CHEMISTRY
(2023)
Review
Pharmacology & Pharmacy
Xiaofan Wu, Hongjian Yang, Xingfei Yu, Jiang-Jiang Qin
Summary: Breast cancer is a common malignancy in women, and HER2 overexpression is associated with poor prognosis. Pertuzumab and trastuzumab are the primary treatment options for early-stage HER2-positive breast cancer, and antibody-drug conjugates and tyrosine kinase inhibitors improve prognosis for metastatic breast cancer patients. However, resistance to targeted therapy is an issue that needs to be addressed.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Chemistry, Applied
Lejiao Jia, Zhenyu Li, Dandan Zheng, Zhiying Li, Zhongxi Zhao
Summary: A novel folic acid mediated chitosan oligosaccharide-grafted disulfide-containing polyethylenimine copolymer-based silica nanohybrids were fabricated for co-delivering paclitaxel and P-shRNA. These nanoparticles efficiently protect P-shRNA against degradation and exhibit excellent antitumor effects on multidrug-resistant breast cancer cells.
CARBOHYDRATE POLYMERS
(2021)
Article
Cell & Tissue Engineering
Yan Qiu, Libo Yang, Honghong Liu, Xiaobo Luo
Summary: The use of the anti-HER2 drug trastuzumab has significantly improved the prognosis of HER2-positive breast cancer patients, but 50% of patients relapse due to trastuzumab resistance, which is closely related to the presence of breast cancer stem cells (BCSCs). BCSCs are resistant to conventional therapy and may drive distant metastasis and cancer relapse.
Review
Pharmacology & Pharmacy
Shiyao Sui, Shouping Xu, Da Pang
Summary: Breast cancer is a significant threat to women's health, and ferroptosis may offer a new direction for breast cancer treatment. However, the complete appearance of ferroptosis in breast cancer and its potential combination with traditional anti-breast cancer drugs remain uncertain. This review explores the roles of various factors associated with ferroptosis in breast cancer, provides evidence of ferroptosis induction by traditional drugs and elimination of breast cancer cells by ferroptosis inducers, and discusses the prospects and potential obstacles of using ferroptosis inducers in breast cancer therapy.
PHARMACOLOGY & THERAPEUTICS
(2022)
Review
Biochemistry & Molecular Biology
Pietro Gentile
Summary: Mesenchymal stem cells (MSCs) have potential in the treatment of breast cancer by delivering anticancer drugs and gene therapy. The safety of fat grafting and adipose-derived MSCs in breast reconstruction has been confirmed. Extracellular vesicles (EVs), as a cell-free therapy, have also been studied in breast cancer treatment.
Review
Oncology
Yi Cao, Yunjin Li, Ruijie Liu, Jianhua Zhou, Kuansong Wang
Summary: HER2 amplification is associated with poor prognosis in breast cancer, but HER2-targeted therapies have shown improved clinical outcomes. However, drug resistance to these therapies is a major challenge. This review discusses the mechanisms of drug resistance in HER2-positive breast cancer and summarizes recent research progress, including preclinical and basic research studies.
Review
Oncology
Linheng Li, Roy A. Jensen
Summary: The use of immunotherapy has revolutionized cancer treatment for certain types of cancers, but its broad utility is limited due to ineffectiveness in many cancer types. This is partly due to the phenotypic plasticity established by cancer stem cells (CSC) and their associated microenvironments, which allows for immune evasion. This article discusses the current understanding of CSC-mediated immune evasion and proposes ways to overcome the immune privilege of CSCs and the immune-suppressive microenvironment.
Article
Oncology
Ambikai Gajan, Ashapurna Sarma, Seongho Kim, Katherine Gurdziel, Gen Sheng Wu, Malathy P. Shekhar
Summary: The study reveals that TNBCs with constitutively hyperactivated PARP-1 have greater tolerances for PARP inhibitors and platinum-based drugs, showing increased cytotoxicity when treated with a combination of olaparib and cisplatin. Despite developing olaparib resistance, TNBC cells retain sensitivity to cisplatin and display alterations in DNA repair pathways. Additionally, differences in cisplatin-induced cellular response pathways are observed between TNBC models with wild type versus mutant BRCA1.
FRONTIERS IN ONCOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Suhail Ahmad Mir, Laraibah Hamid, Ghulam Nabi Bader, Ambreen Shoaib, Mohamed Rahamathulla, Mohammad Y. Alshahrani, Prawez Alam, Faiyaz Shakeel
Summary: Cancer is a major cause of death worldwide, with millions of new cases and deaths reported each year. Chemotherapy, radiotherapy, and surgery are the main approaches to treating cancer, but they have limitations. Lack of target selectivity and drug resistance are major obstacles in cancer treatment. Nanotechnology-based drug therapies have shown great promise in overcoming resistance, with several nano-based drugs being explored at the clinical level.
